NKTR vs. LCFY
NKTR (Nektar Therapeutics) and LCFY (Locafy Ltd) are both stocks. NKTR operates in Biotechnology (Healthcare), while LCFY operates in Internet Content & Information (Communication Services). Over the past 3 years, NKTR returned 97.10%/yr vs -17.58%/yr for LCFY. At a 0.10 correlation, their price movements are largely independent.
Performance
NKTR vs. LCFY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NKTR achieves a 57.73% return, which is significantly higher than LCFY's 36.79% return.
NKTR
- 1D
- 1.51%
- 1M
- 0.12%
- YTD
- 57.73%
- 6M
- 50.00%
- 1Y
- 599.06%
- 3Y*
- 97.10%
- 5Y*
- -23.55%
- 10Y*
- -11.08%
LCFY
- 1D
- -1.54%
- 1M
- -4.25%
- YTD
- 36.79%
- 6M
- 21.59%
- 1Y
- 42.91%
- 3Y*
- -17.58%
- 5Y*
- —
- 10Y*
- —
NKTR vs. LCFY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
NKTR Nektar Therapeutics | 57.73% | 203.08% | 64.60% | -75.00% | -61.50% |
LCFY Locafy Ltd | 36.79% | -59.24% | -24.30% | 53.82% | -91.17% |
Correlation
The correlation between NKTR and LCFY is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Mar 25, 2022 | 0.10 |
Fundamentals
NKTR:
$1.65B
LCFY:
$6.95M
NKTR:
-$8.64
LCFY:
-A$1.44
NKTR:
21.94
LCFY:
2.77
NKTR:
2.86
LCFY:
2.63
NKTR:
$55.63M
LCFY:
A$3.63M
NKTR:
$44.58M
LCFY:
A$3.63M
NKTR:
-$121.05M
LCFY:
-A$803.06K
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NKTR vs. LCFY — Risk / Return Rank
NKTR
LCFY
NKTR vs. LCFY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and Locafy Ltd (LCFY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NKTR | LCFY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.16 | ||
| Sortino ratioReturn per unit of downside risk | +3.64 | ||
| Omega ratioGain probability vs. loss probability | 1.74 | 1.37 | +0.38 |
| Calmar ratioReturn relative to maximum drawdown | 12.99 | 0.63 | +12.36 |
| Martin ratioReturn relative to average drawdown | 27.75 | 0.90 | +26.85 |
Loading charts...
Drawdowns
NKTR vs. LCFY - Drawdown Comparison
The maximum NKTR drawdown since its inception was -99.61%, roughly equal to the maximum LCFY drawdown of -96.59%. Use the drawdown chart below to compare losses from any high point for NKTR and LCFY.
Loading charts...
Drawdown Indicators
| NKTR | LCFY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.61% | -96.59% | -3.02% |
Max Drawdown (1Y)Largest decline over 1 year | -46.54% | -68.07% | +21.53% |
Max Drawdown (3Y)Largest decline over 3 years | -73.20% | -76.75% | +3.55% |
Max Drawdown (5Y)Largest decline over 5 years | -97.76% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -99.61% | — | — |
Current DrawdownCurrent decline from peak | -95.90% | -94.27% | -1.63% |
Average DrawdownAverage peak-to-trough decline | -68.35% | -88.80% | +20.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.74% | 47.67% | -25.93% |
Volatility
NKTR vs. LCFY - Volatility Comparison
The current volatility for Nektar Therapeutics (NKTR) is 14.19%, while Locafy Ltd (LCFY) has a volatility of 17.97%. This indicates that NKTR experiences smaller price fluctuations and is considered to be less risky than LCFY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NKTR | LCFY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.19% | 17.97% | -3.78% |
Volatility (6M)Calculated over the trailing 6-month period | 60.56% | 65.56% | -5.00% |
Volatility (1Y)Calculated over the trailing 1-year period | 181.62% | 249.44% | -67.82% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 121.88% | 174.98% | -53.10% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 97.17% | 174.98% | -77.81% |
Dividends
NKTR vs. LCFY - Dividend Comparison
Neither NKTR nor LCFY has paid dividends to shareholders.
Financials
NKTR vs. LCFY - Financials Comparison
This section allows you to compare key financial metrics between Nektar Therapeutics and Locafy Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NKTR and LCFY have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LCFY has higher volatility (17.97%) compared to NKTR (14.19%). In terms of maximum drawdown, NKTR dropped -99.61% vs LCFY's -96.59%.
NKTR currently has the higher Sharpe Ratio (3.33 vs 0.17), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NKTR and LCFY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer